NCT02037347

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Palifermin Treatment of Toxic Epidermal Necrolysis

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Brett King · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.

Conditions

• Toxic Epidermal Necrolysis
• Stevens-Johnson Syndrome

Interventions

Type	Name	Description
DRUG	Palifermin

Timeline

• Start date: 2010-10-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2014-01-15
• Last updated: 2016-11-30
• Results posted: 2016-11-30

Locations

2 sites across 1 country: United States